-
Annexin V-Cy5 Apoptosis Kit Guide
2026-08-24
The Annexin V-Cy5 Apoptosis Kit supports rapid Annexin V apoptosis detection by labeling exposed phosphatidylserine with Cy5 for fluorescence microscopy or flow cytometry. It is useful as a membrane-level apoptosis assay, but it does not directly measure lysosomal digestion in stressed microglia.
-
ACE Inhibitor Selectivity Across Aminopeptidases
2026-08-24
Tieku and Hooper directly compared metallopeptidase inhibitors against the cell-surface aminopeptidases AP-A, AP-N, and AP-W, revealing substantial differences in inhibitor selectivity. The study shows why ACE inhibitor activity should not be inferred from potency against unrelated zinc aminopeptidases and provides a framework for evaluating off-target effects in peptide-metabolism research.
-
p-Cresyl Sulfate: From Uremia to Biliary Injury
2026-08-23
Explore how p-Cresyl sulfate, or p-tolyl hydrogen sulfate, connects renal retention, endothelial dysfunction, and biliary epithelial injury. This article translates recent mechanistic evidence into practical assay design decisions for integrated uremic toxin research.
-
BMN 673 (Talazoparib) PARP1/2 Inhibitor
2026-08-22
A practical, scenario-based guide to using BMN 673 (Talazoparib) for PARP-dependent viability, proliferation, and DNA-repair studies. It explains how SKU A4153 supports controlled dosing, assay interpretation, and reproducible compound selection across homologous-recombination-deficient and cancer cell models.
-
Catalpol Workflows for Neuroprotection Research
2026-08-22
Catalpol supports mechanism-led workflows spanning neuroinflammation, cognitive impairment, osteoporosis, ischemic stroke, and liver fibrosis models. This practical guide connects formulation, dosing, pathway validation, tissue exposure, and troubleshooting for more reproducible preclinical studies.
-
ATRX Loss and PDGFR Inhibitor Sensitivity in Glioma
2026-08-21
The 2022 Cancers study identified ATRX deficiency as a context associated with increased sensitivity of high-grade glioma cells to receptor tyrosine kinase and PDGFR inhibitors. Its most important translational implication is that ATRX status should be considered when interpreting RTK inhibitor trials and when designing combinations with temozolomide.
-
Muscle-Derived BDNF in Early NMJ Assembly
2026-08-20
The reference study shows that muscle-generated BDNF is a spatially controlled regulator of early neuromuscular junction assembly, rather than merely a diffusible trophic factor. By combining live-cell imaging, molecular perturbation, and skeletal muscle-specific knockout models, the authors connect BDNF trafficking, localized release, and proteolytic processing with acetylcholine receptor clustering.
-
Capsaicin Workflows for TRPV1 and KDM1A Studies
2026-08-20
Capsaicin supports two complementary research tracks: TRPV1-driven sensory assays and KDM1A/LSD1-focused gastric cancer experiments. This practical guide connects concentration planning, orthogonal readouts, and troubleshooting to improve reproducibility in pain, dermatitis, inflammation, and oncology workflows.
-
RSL3 and the Final Phase of Ferroptosis
2026-08-19
RSL3, a selective glutathione peroxidase 4 inhibitor, is more than a ferroptosis trigger: it can reveal how lipid peroxide damage becomes terminal plasma-membrane failure. This article connects RSL3 assay design with new evidence on TMEM16F-mediated lipid scrambling and tumor immune rejection.
-
Human iPSC Intestinal Organoids for Pharmacokinetics
2026-08-19
Saito and colleagues established a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids can be cryopreserved, expanded, and differentiated into intestinal epithelial cells with enterocyte-associated CYP and transporter activities, supporting more human-relevant pharmacokinetic studies than conventional animal or Caco-2 models.
-
p-Cresyl sulfate in CKD Calcification Assays
2026-08-18
Build reproducible uremic-toxin models that connect p-Cresyl sulfate exposure with endothelial dysfunction, valvular calcification, and Klotho/SIRT1 signaling. This workflow emphasizes fresh-solution handling, albumin-aware controls, mechanistic rescue arms, and practical troubleshooting for translational CKD research.
-
p-Cresyl Sulfate and Aortic Valve Calcification
2026-08-18
A 2026 study identifies p-cresyl sulfate as a direct enhancer of calcification in aortic valvular interstitial cells and connects this effect to HIF-1α activation, klotho loss, and NF-κB/RUNX2 signaling. Its porcine cell and rat CKD experiments suggest that restoring klotho activity or activating SIRT1 may provide mechanistic strategies for investigating calcific aortic valve disease in uremic conditions.
-
CHI3L1-IN-5 for Astrocyte Aβ Clearance
2026-08-17
CHI3L1-IN-5, also called Compound Z17, offers a targeted way to connect inflammatory signaling with impaired amyloid handling in human astrocyte models. This practical guide shows how to combine NF-κB, Aβ uptake, and lysosomal readouts while improving dosing, controls, and assay reproducibility.
-
Capsazepine Workflows for TRPV1 Pain Research
2026-08-17
Capsazepine is a practical TRPV1 ion channel antagonist for separating receptor-driven nociception from broader calcium, TRPM8, and apoptosis effects. This workflow connects capsaicin-response assays with the sensory, affective, and mechanistic endpoints highlighted in recent orofacial pain research.
-
Chloramphenicol for Plasmid Selection and AMR Assays
2026-08-16
Chloramphenicol combines defined bacterial translation blockade with flexible plasmid-selection conditions, making it useful for cloning, plasmid stability, and resistance-transfer workflows. This guide connects the reagent to recent carbapenem-resistant Enterobacter cloacae research while emphasizing controls, verification, and troubleshooting.